Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NOVANTRONE vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Treatment of acute nonlymphocytic leukemia (ANLL) in adults (in combination with other agents),Treatment of advanced hormone-refractory prostate cancer (in combination with corticosteroids),Treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (to reduce neurologic disability and frequency of clinical relapses)
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life: 23-215 hours (mean ~37 hours). The long half-life reflects extensive tissue distribution and slow elimination, allowing weekly dosing.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Mitoxantrone is extensively metabolized in the liver via oxidation and conjugation, primarily by cytochrome P450 enzymes, forming inactive metabolites. Elimination is mainly via the hepatobiliary system with fecal excretion; small amounts are excreted renally.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily hepatic (biliary/fecal) elimination: ~25% as unchanged drug and metabolites in feces over 5 days; renal excretion accounts for ~11% (6-11%) as unchanged drug. Less than 10% excreted unchanged in urine.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
~78% bound to plasma proteins (primarily albumin).
Approximately 85-90% bound to serum albumin.
Mean Vd: 8-22 L/kg (range 6-44 L/kg). Large Vd indicates extensive tissue distribution and binding to intracellular components.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Intravenous: 100% (only route of administration). Oral bioavailability is <5% and not clinically relevant; no other routes used.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No dose adjustment required for GFR >50 m L/min. For GFR 10-50 m L/min: administer 75% of normal dose. For GFR <10 m L/min: administer 50% of normal dose.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25%. Child-Pugh Class C: reduce dose by 50%.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Safety and efficacy not established; not recommended for pediatric use.
Not established; safety and efficacy not determined in pediatric patients.
Monitor cardiac function closely due to increased risk of cardiotoxicity. Higher risk of myelosuppression; consider lower initial doses based on renal function (see renal adjustment).
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
1. Mitoxantrone should be administered under the supervision of a physician experienced in the use of cancer chemotherapy agents. 2. Cardiac toxicity, including congestive heart failure, can occur and may be cumulative; risk increases with prior anthracycline use, mediastinal radiotherapy, pre-existing cardiac disease, or concomitant cardiotoxic drugs. 3. Secondary acute myeloid leukemia (AML) has been reported in patients treated with mitoxantrone-containing regimens. 4. Severe myelosuppression will occur.
None.
Cardiotoxicity: Monitor left ventricular ejection fraction (LVEF) before and during therapy; cumulative dose limit of 140 mg/m² in multiple sclerosis patients.,Myelosuppression: Severe neutropenia, thrombocytopenia, and anemia; monitor complete blood counts regularly.,Secondary malignancies: Increased risk of AML and myelodysplastic syndrome.,Hepatic impairment: Dose reduction may be necessary; monitor liver function.,Renal impairment: Use with caution; adjust dose if severe.,Immunosuppression: Increased risk of infections; avoid live vaccines.,Pregnancy: Can cause fetal harm; advise effective contraception.,Extravasation: Can cause tissue necrosis; administer via IV with care.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to mitoxantrone or any component of the formulation,Significant pre-existing bone marrow suppression (e.g., baseline neutrophil count <1500/mm³, platelet count <50,000/mm³),Patients with clinically significant cardiac disease (e.g., myocardial infarction within 6 months, unstable angina, severe heart failure)
Hypersensitivity to AURLUMYN or any of its components.
No known food interactions. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid grapefruit juice as it may theoretically interfere with metabolism, though not clinically significant.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Mitoxantrone is teratogenic in animals and is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of spontaneous abortion and major congenital malformations. Second and third trimester exposure may cause fetal growth restriction, myelosuppression, and cardiac toxicity. Use during pregnancy is contraindicated unless the potential benefit outweighs the risk.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Mitoxantrone is excreted into human breast milk; the milk-to-plasma ratio is not well characterized. Due to the potential for serious adverse reactions in nursing infants, including immunosuppression and cardiotoxicity, breastfeeding is contraindicated during therapy and for at least 1 month after the last dose.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No specific dose adjustments are established for pregnancy. However, pharmacokinetics may be altered due to increased plasma volume and renal clearance. Dose adjustment based on body surface area and close monitoring for toxicity are recommended. Use lowest effective dose and consider alternative therapies if possible.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Mitoxantrone is a topoisomerase II inhibitor and anthracenedione; cumulative lifetime dose should not exceed 140 mg/m² due to dose-dependent cardiotoxicity. Pre-treatment LVEF must be assessed and monitored regularly. Administration requires cardiac monitoring during infusion due to risk of arrhythmias.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Report any shortness of breath, cough, or swelling of ankles/feet immediately as these may indicate heart problems.,Urine may turn blue-green for 24-48 hours after infusion; this is harmless.,Avoid live vaccines during treatment and for 6 months after.,Use effective contraception during and for at least 4 months after therapy due to risk of fetal harm.,Notify your doctor if you experience easy bruising, bleeding, fever, or signs of infection.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NOVANTRONE vs AURLUMYN, answered by our medical review team.
NOVANTRONE is a Antineoplastic Agent that works by Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NOVANTRONE and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NOVANTRONE is: 12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NOVANTRONE and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NOVANTRONE is classified as Category C. Mitoxantrone is teratogenic in animals and is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of spontaneous abortion and major conge. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.